



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Themed Discussions

ID	N.pgm	Title	Presenting Author
<b>20/06/2024 10.05 - 11.05 People living with HIV: thinking of QoL</b>			
447	TD 1	Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study	Antonio Di Biagio, Genova
384	TD 2	Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)	Stefania Arsuffi, Brescia
366	TD 3	Enhancing adherence and treatment satisfaction in people living with HIV: the impact of cabotegravir plus rilpivirine long-acting in real life	Antonio Di Biagio, Genova
260	TD 4	Clinical experience with Doravirine: real-life study of therapeutic efficacy and influence on metabolic profile of dual versus triple antiretroviral regimens in a tertiary hospital of Milan	Riccardo Nardo, Milano
258	TD 5	Rapid ART initiation and Retention in care of people living with HIV: a six-years observational study in foreigners versus Italian-borne	Lidia Gazzola, Milano
<b>20/06/2024 13.15 - 14.15 Antiretroviral therapy: thinking of durability</b>			
33	TD 6	Durability of doravirine-dolutegravir dual combination in a multicenter cohort of elderly people with HIV	Maria Mazzitelli, Padova
408	TD 7	Comparing the efficacy and safety of dolutegravir+lamivudine vs bicitegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens in a multicenter cohort	Arturo Ciccullo, L'Aquila
160	TD 8	Similar Efficacy, Safety and CD4 T cell increase up to Week 96 observed in Fostemsavir (FTR) based regimens from the BRIGHT study and Dolutegravir (DTG) based regimens from the VIKING-3 study in multidrug resistant (MDR) HIV-1 individuals	Antonella Castagna, Milano
383	TD 9	Exploring the Use of Darunavir Boosted plus Dolutegravir in Highly Treatment-Experienced HIV Population: A Retrospective Cohort Study	Andrea De Vito, Alghero
75	TD 10	Real-world data on the effectiveness and safety of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH): 24-month full dataset results of the Italian BICSTaR cohort	Stefano Rusconi, Legnano MI
<b>21/06/2024 11.35 - 12.35 Because the virus matters</b>			
116	TD 11	Viral Blips among People Living with HIV following recommended vaccines	Benedetta Trentacapilli, Milano
472	TD 12	Clinical presentation of newly diagnosed PWH in the last four-years period post COVID-19 pandemic, in a single center in Rome: a retrospective observational study	Andrea Carbone, Roma
158	TD 13	Clinical and Immunovirological Features of Potential Post Treatment HIV Controllers	Stefano Rapino, Brescia
90	TD 14	Two-drugs regimens did not influence HIV-1 DNA in people living with HIV	Gabriele Cavazza, Milano
247	TD 15	Virological performance and resistance-associated mutations in people living with HIV switching to bicitegravir/emtricitabine/tenofovir alafenamide in the Italian ARCA cohort: the BIC-BARRIER Study	Laura Pezzati, Legnano MI



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Themed Discussions

ID	N.pgm	Title	Presenting Author
<b>21/06/2024 13.40 - 14.50 Crossing borders and fighting inequalities</b>			
190	TD 16	Active close contact investigation of tuberculosis through Computer-Aided Detection and stool Xpert MTB/RIF among people living in Oromia region, Ethiopia: a preliminary results	Giacomo Guido, Bari
264	TD 17	The impact of COVID-19 on the Virological Suppression in People Living with HIV Followed up at the Hospital Divina Providência in Luanda, Angola	Andrea Calcagno, Torino
323	TD 18	Trends in HIV-related stigma and gender inequality indicators: findings from a peer-based intervention prevention program in rural northern Uganda	Giulia Micheli, Roma
176	TD 19	High In-hospital Mortality and Significant Prevalence of HIV among Patients Admitted to a Tuberculosis Ward at Divina Providência Hospital in Luanda - Angola, 2023	Ana Sofia Lopes Sucuma, Torino